National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2018

Walker, Tanja Y.; Elam–Evans, Laurie D.; Yankey, David; Markowitz, Lauri E.; Williams, Charnetta; Fredua, Benjamin; Singleton, James A.; Stokley, Shannon

doi:10.15585/mmwr.mm6833a2

Cited by 345 publications

(261 citation statements)

References 10 publications

Supporting

Mentioning

248

Contrasting

Unclassified

Order By: Relevance

“…23 The estimated MenACWY vaccine coverage of individuals aged 13 to 17 years in 2018 was 86.6% for ≥1 dose and 50.8% for ≥2 doses. 37 In contrast, MenB vaccine uptake is much lower, with only an estimated 17.2% of individuals aged 17 years having received ≥1 dose of a multidose vaccine series in 2018 37 and an estimated <50% complete the series. 38 Patients and parents rely on their physicians to guide decisions about vaccination, 23,30,39 and pediatricians in turn rely on clear guidance and support from the ACIP regarding how vaccines should be prescribed to their patients.…”

Section: Almost Always U S U a L L Ymentioning

confidence: 99%

Disparities in healthcare providers’ interpretations and implementations of ACIP’s meningococcal vaccine recommendations

Huang

Goren

Lee

et al. 2019

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Invasive meningococcal disease (IMD) caused by the bacteria Neisseria meningitidis is rare but potentially fatal. For healthy adolescents, the US Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination with MenACWY and recommends MenB vaccination under shared clinical decision-making (previously "Category B"). The recommendation for MenB vaccination was the first category B recommendation in adolescents, and it is unclear how healthcare providers (HCPs) implement these guidelines. This 2017 web-based survey of US HCPs explored characteristics associated with prescribing or receiving MenB and MenACWY vaccines, HCP knowledge of vaccine recommendations, and real-world practice patterns. Of 529 respondents, 436 prescribed MenB vaccines to their eligible adolescent/young adult patients and 93 prescribed MenACWY vaccines only. MenB vaccine prescribers were more likely to be pediatricians compared with MenACWY vaccine only prescribers, and patients who received MenB vaccines were more likely to be non-Hispanic whites living in shared spaces (eg, college dormitories) than those not receiving the vaccine. Seventy-seven percent of HCPs indicated that they prescribe MenACWY vaccines consistently with ACIP recommendations (to all members of an age group), whereas only 7% indicated that they prescribe MenB vaccines consistently with ACIP recommendations (individual clinical decision making). Patientrelated factors, disease-related factors, and guidelines all influenced HCP decisions to prescribe meningococcal vaccines. Providing HCPs with clear guidance on how to initiate discussion of MenB vaccines with patients and their caregivers may aid in fully protecting US adolescents against meningococcal disease caused by 5 of the disease-causing serogroups. ARTICLE HISTORY

show abstract

Section: Almost Always U S U a L L Ymentioning

confidence: 99%

Disparities in healthcare providers’ interpretations and implementations of ACIP’s meningococcal vaccine recommendations

Huang

Goren

Lee

et al. 2019

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…These MenB vaccines are not interchangeable, and the same vaccine should be used for all administered doses . The US Advisory Committee on Immunization Practices (ACIP) recommends that a MenB vaccine series may be administered to individuals aged 16‐23 years, and data from the National Immunization Survey in 2018 demonstrate that only 17.2% of 17‐year‐olds received at least one MenB vaccine dose (≥2 doses are recommended for those electing vaccination) . The clinical experience with MenB‐4C has previously been reviewed, whereas recent publication of MenB‐FHbp pivotal phase 3 studies in adolescents and young adults provides an opportunity to comprehensively review available data on MenB‐FHbp clinical use.…”

Section: What Is Known and Objectivementioning

confidence: 99%

A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB‐FHbp

Alderfer

Snow

2019

J Clin Pharm Ther

View full text Add to dashboard Cite

What is known and objective This review describes invasive meningococcal disease (IMD) epidemiology in the United States, provides a brief overview of available meningococcal vaccines and discusses meningococcal serogroup B (MenB) vaccine development. Particular focus is given to the recombinant protein MenB vaccine, MenB‐FHbp (Trumenba®, bivalent rLP2086) in light of recent publication of phase 3 data; the other MenB vaccine (Bexsero®, MenB‐4C) has been recently reviewed. Current recommendations of the US Advisory Committee on Immunization Practices (ACIP) for MenB vaccination and potential barriers to immunization are also discussed. Methods Using the published literature, this article reviews the development and use of MenB‐FHbp to date, with a focus on the United States. Results and discussion Despite the availability of medical treatment, IMD is associated with significant mortality and frequently occurring serious permanent sequelae in surviving individuals. Worldwide, most IMD is caused by six serogroups (A, B, C, W, X and Y). MenB is the most common disease‐causing meningococcal serogroup in the United States and has caused several recent university‐based IMD outbreaks. MenB vaccines, including MenB‐FHbp, are available in the United States. ACIP recommends that all individuals ≥10 years of age at increased risk for meningococcal disease receive MenB vaccination; healthy individuals 16‐23 years of age are recommended MenB vaccines based on individual clinical decision‐making. MenB‐FHbp is used on a 2‐dose schedule (0, 6 months) when vaccinating healthy individuals and on a tailored 3‐dose schedule (0, 1‒2, 6 months) in cases of increased risk. What is new and conclusion Because vaccination provides the most effective protection against IMD, pharmacists are in an excellent position to offer evidence‐based vaccine information, as well as to encourage and provide meningococcal immunizations to adolescents and young adults.

show abstract

“…HPV vaccines, highly effective at preventing HPV infection, have been available since 2006 for females and since 2009 for males. However, in 2018, only 68% of US adolescents aged 13‐17 years had started the vaccination series and only 51% of adolescents had finished it …”

Section: Introductionmentioning

confidence: 99%

The potential population‐based impact of an HPV vaccination intervention in Colorado

et al. 2019

View full text Add to dashboard Cite

Background Human papillomavirus (HPV) infection is the most common cause of cervical cancer and can be prevented with vaccination, but HPV vaccination rates remain low. An intervention to improve health care provider communication about vaccination has been shown to increase HPV vaccination rates in an initial trial in Colorado, where about 160 cases of cervical cancer are diagnosed each year. Methods Census data were combined with Colorado cancer and immunization registry data to identify clinics in locations that would most benefit from implementation of this intervention to improve HPV vaccination rates. ArcGIS Pro was used to map cervical cancer incidence, immunization rates, population data, and location of clinics participating in practice‐based research networks (PBRNs). Results from the provider communication intervention trial and published estimates of the number needed to vaccinate to prevent a case of cervical cancer were used to predict the number of cervical cancer cases prevented based on increased vaccination due to the intervention. Results Ninety‐eight Colorado PBRN clinics were analyzed. For the 10 clinics with the highest predicted number of cervical cancer cases prevented, 5218 additional patients would be vaccinated and 43 cervical cancer cases prevented with implementation of the intervention. If implemented in all 98 clinics, the intervention would lead to 20 490 additional patients vaccinated (range 7‐658/clinic) and 171 cases of cervical cancer prevented (range 0.05‐5.48/clinic). Conclusions Geographic data from cancer and immunization registries can inform the dissemination of evidence‐based practices like the provider communication intervention for HPV vaccination to maximize impact on public health.

show abstract

National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2018

Cited by 345 publications

References 10 publications

Disparities in healthcare providers’ interpretations and implementations of ACIP’s meningococcal vaccine recommendations

Disparities in healthcare providers’ interpretations and implementations of ACIP’s meningococcal vaccine recommendations

A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB‐FHbp

The potential population‐based impact of an HPV vaccination intervention in Colorado

Contact Info

Product

Resources

About